Manufacturing: MaSTherCell

Orgenesis is a premier service provider in the regenerative medicine industry. Orgenesis provides contract development and manufacturing (CDMO) services for many of the world’s leading pharmaceutical and biotech companies, as well as research institutions and hospitals involved in cutting edge cell therapy.

Advanced Cell Therapies

Transdifferentiation Platform
Lead Indication: Severe diabetes following Total Pancreatectomy (TP), an orphan drug indication

Through our subsidiary Orgenesis Ltd., Orgenesis has developed a unique, proprietary technology platform that transforms the patient’s own liver cell into a fully functional and physiologically glucose-responsive insulin-producing cell, designed to provide long-term insulin independence.